Abhishek Kumar, MD
Pulmonary Disease · Las Vegas, NVNPI 1639443823
Payments from drug & device makers
What this record shows
This record is dominated by education: $52,500 of the $73,928 with a category attached, or 71.0%. Intuitive Surgical accounts for 96.2% of it on its own, with 26 other manufacturers making up the rest. Among pulmonary disease clinicians in NV with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 171 payments — averaging $432.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Intuitive Surgical$71K
- Pulmonx Corporation$1K
- GSK$231
- AstraZeneca$202
- United Therapeutics Corporation$139
- Penumbra, Inc.$137
- plus $868 from 21 others
Across 4 payments — averaging $2709.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Gyrus ACMI, Inc.$11K
What the payments were for
- Speaking & faculty fees$8,00011%
- Travel & lodging$7,04210%
- Food & beverage$6,3729%
- Education$52,50071%
- Gifts$140%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Intuitive Surgical | 87 | $71,119 |
| Pulmonx Corporation | 8 | $1,233 |
| GSK | 19 | $231 |
| AstraZeneca | 13 | $202 |
| United Therapeutics Corporation | 1 | $139 |
| Penumbra, Inc. | 1 | $137 |
| Olympus America Inc. | 2 | $92 |
| Grifols USA, LLC | 4 | $88 |
| Merck | 4 | $72 |
| Genentech USA, Inc. | 5 | $70 |
| Mylan Specialty L.p. | 3 | $65 |
| Gyrus ACMI, Inc. | 1 | $60 |
| Boehringer Ingelheim | 3 | $57 |
| Sanofi | 3 | $48 |
| Kls-martin L.p. | 1 | $48 |
| Sunovion Pharmaceuticals Inc. | 2 | $41 |
| Philips North America LLC | 2 | $35 |
| Amgen | 1 | $30 |
| Circassia Inc. | 2 | $27 |
| Shire North American Group Inc | 2 | $25 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $20 |
| La Jolla Pharmaceutical Company | 1 | $18 |
| Medtronic | 1 | $17 |
| Advanced Respiratory, Inc | 1 | $15 |
| Collegium Pharmaceutical, Inc. | 1 | $15 |
| E.r. Squibb & Sons, L.L.C. | 1 | $14 |
| Veran Medical Technologies, Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Da Vinci Surgical System$62,837
- DA VINCI SP$4,000
- DAVINCI XI$3,000
- ZEPHYR ENDOBRONCHIAL VALVE$1,035
- TYVASO$139
- Indigo System$137
- CHARTIS CATHETER$130
- ZEPHYR DELIVERY CATHETER$130
- PULMONX CHARTIS TABLET CONSOLE$130
How this compares
$73,928 in reported general payments places this provider in the 95th percentile of 84 pulmonary disease providers in Nevada.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 31 | $19,280 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 16 | $8,379 |
| Levofloxacin | 12 | $40 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Anoro Ellipta | $231 | $27,65947 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 84 pulmonary disease providers in Nevada.
Other pulmonary disease in Las Vegas
- Arthur RomeroLas Vegas$310K
- Lloyd DelmundoLas Vegas$150K
- Naresh SinghLas Vegas$111K
- Jerome HruskaLas Vegas$72K
- Vishisht MehtaLas Vegas$22K
- Kamran KhanLas Vegas$17K
- John WojcikLas Vegas$14K
- Walter WilloughbyLas Vegas$10K
- Robert LampertLas Vegas$8K
- Rachakonda PrabhuLas Vegas$7K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.